mrpts

MULTIDISCIPLINARY RADIOPHARMACEUTICAL THERAPY SYMPOSIUM

From Innovation to Impact: Advancing Radiopharmaceutical Therapy Together

March 18-19, 2027 | WESTFIELDS MARRIOTT | CHANTILLY, VA



Industry Satellite Symposium

Application Deadline: December 17, 2026

www.rptsymposium.org

Industry Satellite Symposium

Overview

These guidelines, based on policies approved by ASTRO's Board of Directors, are designed to assist you in preparing your application to present an Industry Satellite Symposium (ISS) in conjunction with the 2027 Multidisciplinary Radiopharmaceutical Therapy Symposium.

These rules and regulations are in addition to policies outlined in the 2027 Multidisciplinary Radiopharmaceutical Therapy Symposium Exhibitor Rules, Regulations and Policies, available online at www.astro.org/RPT27rules, regarding use of the ASTRO name and/or logo and mailing lists.

Important Dates

Application Deadline*	December 17, 2026
Approval Notification Sent	Early-January, 2027
Marketing Materials Due**	February 1, 2027
Preshow List Request Due	February 8, 2027
Program Fee Due	February 26, 2027
Evaluation Summary Due	May 3, 2027

**Late applications and any other materials submitted past their stated deadlines will be delayed in processing and approval by ASTRO.*

***ASTRO must approve your marketing materials before you print/distribute, so please keep this in mind when developing your own timeline.*

Guidelines

Definition

Industry Satellite Symposium (ISS) refers to any educational activity that is independently organized and held in conjunction with the 2027 Multidisciplinary Radiopharmaceutical Therapy Symposium. This includes any educational activity that carries Continuing Medical Education (CME) credit and is not sponsored by the American Society for Radiation Oncology (ASTRO).

Application Process

The organization interested in holding an ISS shall submit a written application (Appendix A) and a completed Letter of Agreement (Appendix B) to ASTRO's Education Department by **December 17, 2026**. Applications will be reviewed by ASTRO's Education Department. Time and space constraints may limit the number of opportunities available.

Compliance

Upon approval, the ISS CME provider will be invoiced. The supporter will be invited to participate with the expectation that the educational activity is held in accordance with the standards established by the Accreditation Council for Continuing Medical Education (ACCME), the AdvaMed Code of Ethics on Interactions with Health Care Professionals, the American Medical Association's (AMA) Code of Ethics Opinion relating to Continuing Medical Education and Gifts to Physicians from Industry, the Food and Drug Administration (FDA) regulations regarding Industry Supported Scientific and Educational Activities, the Medical Imaging and Technology Alliance (MITA) Code of Ethics on Interactions with Health Care Providers, the National Electronic Manufacturers Association (NEMA) Code of Ethics on Interactions with Health Care Providers, the Pharmaceutical Research and Manufacturers of America (PhRMA) Code on Interactions with Health Care Professionals and the Department of Health and Human Services' Office of Inspector General (OIG) Compliance Program Guidance for Pharmaceutical Manufacturers. It is strongly recommended that appropriate source and reference citations accompany all data presented in slides and program materials.

Programs must be final upon submission. Incomplete applications will not be reviewed.

> **Please email your completed application to education@astro.org.**

Eligibility Criteria

The organization must adhere to the following criteria:

- Fulfill any funding obligations (see Appendix D).
- Hold ASTRO harmless from any and all claims that may result from the program.

ASTRO reserves the right to:

- Reject any proposal that does not meet the criteria set forth in these guidelines.
- Reject any proposal for reasons solely determined by ASTRO, including a decision to limit the number of industry-organized activities at the 2027 Multidisciplinary Radiopharmaceutical Therapy Symposium.
- Consult with the organization to assure appropriateness of activity outcome.

Audit

To ensure compliance, your program will be reviewed and may be audited by members of the Symposium Steering Committee.

Guidelines (continued)

Program Content

- Program must be a CME-accredited educational activity.
- Program content must be developed independently, free of bias and cannot overlap with content currently being presented at the 2027 Multidisciplinary Radiopharmaceutical Therapy Symposium.
- Program title must be indicative of the ISS content.
- Objectives must clearly meet the educational needs of the target audience.
- Program must be presented in an objective, balanced and scientifically rigorous manner, cannot commercially promote a specific drug, product or service and must meet the policies and guidelines of the ACCME.
- Content and related materials must promote evidence-based learning for optimum patient outcomes and patient safety.
- Content cannot promote a specific proprietary business interest of a commercial entity.
- Presentation must be fair and balanced when discussing specific products. If trade names are included in your presentation, trade names for several companies must be used where available.
- The symposium provider must provide ASTRO with an evaluation summary once the program is complete.

Role of Faculty

- Participating faculty must disclose all relevant relationships/interests to the review committee and attendees to determine any conflicts of interest.
- Faculty must be independent subject matter experts, scientists and/or clinicians.
- Faculty must present an evidence-based, balanced presentation with a rigorous scientific review.
- Product-specific promotional material or advertisement of any type is prohibited during the presentation.

Leadership Participation

Elected officials and chairs of committees and subcommittees directly and currently involved in the 2027 Multidisciplinary Radiopharmaceutical Therapy Symposium CME program are prohibited from participation in Industry Satellite Symposia, except as attendees who receive no honoraria or reimbursement. See Appendix C for a complete listing. ASTRO reserves the right to reject any proposed faculty member or planner that it deems may have a conflict of interest with Symposium activities.

> **If you have questions on a speaker's eligibility to participate, please contact ASTRO at education@astro.org.**

Scheduling

The following dates and times are available for ISS (one per time slot):

Thursday, March 18, 2027
12:00 p.m. - 1:00 p.m.
Or after 6:00 p.m.

Friday, March 19, 2027
12:15 p.m. - 1:15 p.m.

Guidelines (continued)

Promotion/Marketing

ASTRO encourages independent promotion of approved symposia. ASTRO must approve the content of all such material prior to printing, distribution or posting on the internet. All marketing materials should be sent for review to education@astro.org no later than **February 1, 2027**. Invitations and announcements addressed to meeting registrants should clearly indicate the name(s) of the organization(s) funding the program and the CME provider and must adhere to the following ASTRO logo use:

- The names **American Society for Radiation Oncology** and **Multidisciplinary Radiopharmaceutical Therapy Symposium**, the acronyms ASTRO and MRPTS, and the ASTRO and Multidisciplinary Radiopharmaceutical Therapy logos are registered trademarks of the American Society for Radiation Oncology. Except as explicitly indicated in these ISS Guidelines, use of any other mark owned by ASTRO in conjunction with promotional materials, advertisements, email marketing, company websites, endorsements, statements, contests, and/or awards in conjunction with the ISS is strictly prohibited. Further, the names American Society for Radiation Oncology and Multidisciplinary Radiopharmaceutical Therapy Symposium, the acronyms ASTRO and MRPTS, or any other ASTRO registered trademark may not be used in a company name, website address, email signature/tagline, or to promote the ISS.

Promotional, marketing and on-site materials for the ISS must contain the following statement:

The American Society for Radiation Oncology (ASTRO) has reviewed and approved this symposium as appropriate for presentation as an Industry Satellite Symposium (ISS). The ISS constitutes the content and views of the sponsor and is not part of the official 2027 Multidisciplinary Radiopharmaceutical Therapy Symposium program.

If the ISS is adhering to the deadlines and ASTRO is able to approve relevant materials on time, ASTRO will promote the program in the following methods:

- Listing on the meeting website (www.rptsymposium.org)
- Listing in the Pocket Program
- Complimentary Registration Bag Insert (insert to be provided by sponsor by deadline)
- Verbal mention in the opening welcome of the Symposium
- Meeting signage advertising ancillary events
- Mention on ASTRO's social media platforms

To assist with your marketing efforts, ASTRO will provide a complimentary 2027 Multidisciplinary Radiopharmaceutical Therapy Symposium preshow attendee mailing list at your request once marketing materials are approved by ASTRO:

The list is for a one-time use only. Due to privacy reasons, we do not include email addresses or phone numbers in the lists. Preshow attendees lists are not released earlier than four weeks out from the meeting.

> The list request deadline is **February 8, 2027**. Email your request to education@astro.org and allow 10 business days for processing from the time of order placement.

Note that ASTRO does not guarantee audience size and shall not be held responsible if attendee numbers are lower than original projections. Please note that per ACCME requirements, attendees will be given the option to decline to have their name and contact information included on this mailing list.
The following requirements must be observed prior to, during and following the event:

- The ISS will be an "invitation" event. Provider will have the option to welcome walk-ins.
- No commercial displays will be allowed in the meeting room at any time.

Guidelines (continued)

- No sales or product promotion to attendees is allowed before, during or after the symposium as an adjunct to the meeting program.
- Satellite activities are not acceptable substitutes for activities that are designed to occur during the exhibit program.
- One sign (no larger than a meter board sign) promoting the ISS may be displayed in the registration area on the day of the ISS.
- Signage and distribution of ISS flyers and invitations are permitted at the presenter's booth in the Exhibit Hall or in areas authorized and approved by ASTRO.
- Signage production, setup and dismantling are the provider's responsibility.

Evaluation Summary

All Industry Satellite Symposia providers must send ASTRO a summary report of attendees' evaluations of the program collected in conformance with ACCME requirements. Attendees must be asked to evaluate the program for objectivity and the presence of commercial bias.

> Evaluation results are to be included in a summary report that must be provided to ASTRO at education@astro.org by **May 3, 2027.**

Appendix A

Application to Hold an Industry Satellite Symposium

DEADLINE FOR SUBMISSION: DECEMBER 17, 2026

In addition to this form, applicants must include the following information:

- Program title, title of presentations, confirmed speaker names and learning objectives
- $1,000 nonrefundable application fee

NAME OF ISS

PLEASE INDICATE WHEN YOU PROPOSE TO HOLD YOUR EVENT. Time and space may limit the availability of symposium scheduled.

DATE START TIME END TIME

MEETING/EVENT SPECIFICATIONS

☐ Lunch ☐ Dinner ☐ Reception ☐ Meeting ☐ Other_____

MEETING/EVENT SETUP

The meeting space will be set in banquet rounds for all sessions, to include a stage, head table to seat six panelists and a podium.

ANTICIPATED ATTENDANCE

SUPPORTING COMPANY/CORPORATE MEMBER

MAILING ADDRESS CITY STATE ZIP

CONTACT PERSON

EMAIL PHONE CORPORATE WEBSITE

THIRD PARTY COMPANY IF APPLICABLE (UNDER CONTRACT TO SUPPORTING COMPANY)

This application must be received by ASTRO no later than 5:00 p.m. Eastern time on December 17, 2026. Send your completed application to ASTRO's Education Department via email to education@astro.org.

Preliminary approval of this application authorizes the applicant to proceed with making arrangements for the proposed activity.

Questions? Please contact ASTRO's Education Department at 703-502-1550.

Appendix A (continued)

Application to Hold an Industry Satellite Symposium

Note: Once the symposium is approved by ASTRO, please expect to forward us any materials to be used by presenters as well as a confirmed faculty listing, curriculum vitae and conflict of interest disclosures. If that information is available now, please include it with your application. Once the symposium is completed, please forward a copy of your final evaluation summary report to ASTRO by **May 3, 2027.**

PLEASE COMPLETE THE FOLLOWING:

Offer a statement of educational need that will be met by the session with backup documentation of the determination of that need. Please include a program agenda with your application. A tentative list of faculty is appreciated at this time.

List the learning objectives of the ISS.

List titles of all topics and topic descriptions.

Provide a description of the evaluation process (with sample evaluation forms and how results will be reported in a summary report to ASTRO).

Provide a description of the ISS's target audience, invitation process and verification plan for attendance.

Summarize how faculty and planning committee disclosure information will be communicated to attendees.

Summarize how conflicts of interest are to be managed among ISS planning committee members and presentation faculty.

☐ Check here if you plan to repurpose the content into an enduring material.

Appendix B

Letter of Agreement

Note: Applicants must provide to ASTRO a Letter of Agreement between the Commercial Supporter and Third Party Company (CME Provider). The example provided here in Appendix B may be used, or the applicant may submit a Letter of Agreement that is in a different format.

BETWEEN **AND THE COMMERCIAL SUPPORTER**

CME PROVIDER

COMPANY NAME

ADDRESS

CITY STATE ZIP

TELEPHONE CONTACT PERSON

TITLE OF CME ACTIVITY LOCATION DATE(S)

The above commercial supporter wishes to provide support for the named continuing medical education activity by means of an educational grant for support of the CME activity in the amount of $_____.

CONDITIONS

1. STATEMENT OF PURPOSE: Program is for scientific and educational purposes only and will not promote the company's products, directly or indirectly.
2. CONTROL OF CONTENT AND SELECTION OF PRESENTERS AND MODERATORS: Provider is responsible for control of content and selection of presenters and moderators. The company agrees not to direct the content of the program. The company, or its agents, will respond only to provider-initiated requests for suggestions of presenters or sources of possible presenters. The company will suggest more than one name (if possible); will provide speaker qualifications; will disclose financial or other relationships between company and speaker; and will provide this information in writing. Provider will record role of company, or its agents, in suggesting presenter(s); will seek suggestions from other sources; and will make selection of presenter(s) based on balance and independence.
3. DISCLOSURE OF FINANCIAL RELATIONSHIPS: Provider will ensure meaningful disclosure to the audience, at the time of the program, of (a) company funding and (b) any significant relationship between the provider and the company (e.g., grant recipient) or between individual speakers or moderators and the company.
4. INVOLVEMENT IN CONTENT: There will be no "scripting," emphasis or direction of content by the company or its agents.
5. ANCILLARY PROMOTIONAL ACTIVITIES: No promotional activities will be permitted in the same room or obligate path as the educational activity. No product advertisements will be permitted in the program room.
6. OBJECTIVITY AND BALANCE: Provider will make every effort to ensure that data regarding the company's products (or competing products) are objectively selected and presented, with favorable and unfavorable information and balanced discussion of prevailing information on the product(s) and/or alternative treatments.
7. LIMITATIONS OF DATA: Provider will ensure, to the extent possible, meaningful disclosure of limitations on data (e.g., ongoing research, interim analyses, preliminary data or unsupported opinion).
8. DISCUSSION OF UNAPPROVED USES: Provider will require that presenters disclose when a product is not approved in the United States for the use under discussion.
9. OPPORTUNITIES FOR DEBATE: Provider will ensure meaningful opportunities for questioning or scientific debate.
10. INDEPENDENCE OF PROVIDER IN THE USE OF CONTRIBUTED FUNDS:
    a. Funds should be in the form of an educational grant made payable to the_____ (CME Provider).
    b. No other funds from the commercial company will be paid to the program director, faculty or others involved with the CME activity (additional honoraria, extra social events, etc.).
11. Hold ASTRO harmless from any and all claims that may result from the program.

The commercial supporter agrees to abide by all requirements of the ACCME Standards for Commercial Support of Continuing Medical Education.

THE ACCREDITED PROVIDER AGREES TO: 1) abide by the ACCME Standards for Commercial Support of Continuing Medical Education; 2) acknowledge educational support from the commercial company in program brochures, syllabi and other program materials and 3) upon request, furnish the commercial supporter a report concerning the expenditure of the funds provided.

AGREED

COMMERCIAL COMPANY REPRESENTATIVE (NAME)

SIGNATURE DATE

CME PROVIDER

SIGNATURE DATE

Appendix C and D

Appendix C: Regulations Regarding Leadership Participation

Appendix D: Financial Considerations

Appendix C: Regulations Regarding Leadership Participation

Elected officials and chairs of committees and subcommittees directly and currently involved in the 2027 Multidisciplinary Radiopharmaceutical Therapy Symposium CME program are prohibited from participation in Industry Satellite Symposia, except as attendees who receive no honoraria or reimbursement. These include the following:

- ASTRO Board of Directors
- ASTRO Education Committee Chair and Vice Chair
- ASTRO CME/MOC Committee Co-chairs
- 2027 Multidisciplinary Radiopharmaceutical Therapy Symposium Planning Committee

ASTRO reserves the right to reject any proposal that it deems necessary based on conflict of interest. If you have questions regarding a speaker's eligibility to participate, please contact ASTRO at education@astro.org.

Appendix D: Financial Considerations

APPLICATION FEE

A $1,000 nonrefundable application fee must accompany your application. This fee covers ASTRO administrative costs associated with processing the application.

ISS PROGRAM FEE

Upon ASTRO approval of the symposium, the ISS provider will be invoiced for $20,000 for the program fee. Payment must be received by **February 26, 2027.**

DIRECT COSTS

The ISS provider will be responsible for the management of their event's logistics and for payment of direct costs associated with event promotion, presenters and catering.

PROVIDED SERVICES

The following services are included in the cost of the Industry Satellite Symposium:

- Assignment of day and time.
- Audio visual equipment to include:
  - Two LCD projectors.
  - Two screens.
  - One lectern with microphone.
  - One speaker confidence monitor.
  - Two table microphones.
  - One laser pointer.
  - One speaker timer.
  - One camera to record presentation.
  - Sound amplification and mixer system.
  - VGA switcher.
  - One on-site technician.
- Video and Audio Package capturing each session with links to be provided three weeks post-meeting.
- Expenses for audio visual services incurred beyond what is provided may be acquired through ASTRO's exclusive audio visual vendor at the expense of the ISS provider.
- The Industry Satellite Symposium session will not be included as part of ASTRO's virtual meeting or the onDemand platform.
- Industry Satellite Symposium session listed in the Pocket Program and on the event website.
- Program signage outside of the Industry Satellite Symposium.
- Sponsor may opt to stream live via Zoom link provided by ASTRO, but all speakers must be in person.

Projection is ASTRO's official audio visual vendor and any additional audio visual requirements must by ordered through Projection and NOT another audio visual company unless authorized by ASTRO. Please note, by using another audio visual company, ASTRO will not be responsible for the cost or functionality of any audio visual equipment or labor. The included audio visual is only applicable if provided by Projection.

Payment

CANCELLATION POLICY

- Please note the $1,000 application fee is nonrefundable.
- 50% of the total program fee will be retained for cancellations received on or before **February 26, 2027**.
- 100% of the total program fee will be retained for cancellations received after **February 26, 2027**.
- All cancellations must be made in writing.

PAYMENT INFORMATION

All payments must be received by February 26, 2027. Please email Application and Contract to education@astro.org.

ACH/WIRE PAYMENT (PREFERRED METHOD)

ACH:
American Society for Radiation Oncology
Bank Name: Bank of America Merrill Lynch
Account Number: 0000 2689 5309
ABA/Routing Number: 051000017

Wire Details:
American Society for Radiation Oncology
Account Number: 0000 2689 5309
ABA/Routing Number: 026009593
SWIFT Code: BOFAUS3N
Bank Name: Bank of America
Merrill Lynch
Bank Address: P.O. Box 27025, Richmond, VA 23261-7025

CHECK PAYMENT

Please mail original application with check made payable to ASTRO to:

For Standard Mail:
ASTRO
P.O. Box 418075
Boston, MA 02241-8075

For Overnight Delivery:
Bank of America, Merrill Lynch Lockbox Services
Lockbox #418075, MA5-527-02-07
2 Morrissey Blvd.,
Dorchester, MA 02125

QUESTIONS?

Please contact: Chloe Mujwit | Phone: 703-839-7344 | Email: chloe.mujwit@astro.org